EMA Withdrawn: Tredaptive (laropiprant;nicotinic acid) — Merck Sharp Dohme Ltd.

View source ↗

Summary

EMA has withdrawn Tredaptive (laropiprant and nicotinic acid) from the market, in the dyslipidemias therapeutic area.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemias

Drugs mentioned

• TREDAPTIVE (niacin/laropiprant)

Snippet

Status: Withdrawn. Therapeutic area: Dyslipidemias. MAH: Merck Sharp Dohme Ltd.. Decision date: 10/04/2013